Physician profile
Michael B Whitlow
NPI 1669431979
$4,963.13
in general payments reported to CMS, 2019-2025
20 companies · $2,334 in 2025
The $2,334 reported for 2025 was more than what a typical Clinical & Laboratory Dermatological Immunology provider received nationally (typical 2025 total: $1,130).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.43 · 2021: $15.00 · 2022: $94.78 · 2023: $728 · 2024: $1,769 · 2025: $2,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,633 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,632.93 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,253.39 | 2023-2025 | Rinvoq |
| Janssen Biotech, INC. | $776.40 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $446.07 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $399.18 | 2024-2025 | |
| Pfizer INC. | $343.56 | 2023-2025 | |
| Ucb, INC. | $341.84 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $259.09 | 2023-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $213.96 | 2023-2025 | Taltz, Ebglyss, Zepbound |
| Amgen INC. | $185.61 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $176.44 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $171.78 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $160.46 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $49.98 | 2025 | |
| Arcutis Biotherapeutics, INC. | $44.27 | 2023-2025 | Zoryve |
| Allergan, INC. | $36.43 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $29.79 | 2025 | |
| Almirall LLC | $25.00 | 2025 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.77 | 2023 | Jublia |
| Regeneron Healthcare Solutions, INC. | $16.55 | 2025 | Libtayo |
| Journey Medical Corporation | $13.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Whitlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.